{"name":"SANDOZ INC","slug":"sandoz-inc","ticker":"","exchange":"","domain":"sandoz.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-19","label":"Canasa Phase 3 readout (Ulcerative Colitis (UC))","drug":"Canasa","drugSlug":"canasa","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"ZIEXTENZO Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"ZIEXTENZO","drugSlug":"pegfilgrastim-bmez","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"ZIEXTENZO Phase 2 readout (Renal Pelvis and Ureter Urothelial Carcinoma)","drug":"ZIEXTENZO","drugSlug":"pegfilgrastim-bmez","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-31","label":"Canasa Phase 2 readout (Ulcerative Colitis, Fecal Microbiota Transplantation)","drug":"Canasa","drugSlug":"canasa","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":17,"colorKey":"respiratory","drugs":[{"name":"Depakote DR Tablets","genericName":"Depakote DR Tablets","slug":"depakote-dr-tablets","indication":"Other","status":"phase_1"},{"name":"JUBBONTI","genericName":"DENOSUMAB-BBDZ","slug":"denosumab-bbdz","indication":"Other","status":"marketed"},{"name":"Opana","genericName":"Opana","slug":"opana","indication":"Other","status":"marketed"},{"name":"ANTI-ANGIN® FORMULA","genericName":"ANTI-ANGIN® FORMULA","slug":"anti-angin-formula","indication":"Angina pectoris (stable and unstable)","status":"phase_3"},{"name":"Broncho-munal®","genericName":"Broncho-munal®","slug":"broncho-munal","indication":"Other","status":"phase_3"},{"name":"Canasa","genericName":"Canasa","slug":"canasa","indication":"Other","status":"discontinued"},{"name":"Duragesic","genericName":"Duragesic","slug":"duragesic","indication":"Other","status":"marketed"},{"name":"ENZEEVU","genericName":"AFLIBERCEPT-ABZV","slug":"aflibercept-abzv","indication":"Other","status":"marketed"},{"name":"GME751","genericName":"GME751","slug":"gme751","indication":"Unknown","status":"phase_3"},{"name":"GP2013","genericName":"GP2013","slug":"gp2013","indication":"Other","status":"phase_3"},{"name":"GP2015","genericName":"GP2015","slug":"gp2015","indication":"Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy","status":"phase_3"},{"name":"Generic tacrolimus","genericName":"Generic tacrolimus","slug":"generic-tacrolimus","indication":"Other","status":"marketed"},{"name":"Glimid","genericName":"GLUTETHIMIDE","slug":"glutethimide","indication":"Insomnia","status":"marketed"},{"name":"Glucophage 1000 mg","genericName":"Glucophage 1000 mg","slug":"glucophage-1000-mg","indication":"Other","status":"phase_1"},{"name":"HX575 recombinant human erythropoietin alfa","genericName":"HX575 recombinant human erythropoietin alfa","slug":"hx575-recombinant-human-erythropoietin-alfa","indication":"Other","status":"marketed"},{"name":"Omnitrope","genericName":"Omnitrope","slug":"omnitrope","indication":"Growth retardation","status":"marketed"},{"name":"ZIEXTENZO","genericName":"PEGFILGRASTIM-BMEZ","slug":"pegfilgrastim-bmez","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"EP2006","genericName":"EP2006","slug":"ep2006","indication":"Anemia in patients with chronic kidney disease","status":"phase_3"},{"name":"ERYPO®, Janssen-Cilag","genericName":"ERYPO®, Janssen-Cilag","slug":"erypo-janssen-cilag","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"HYRIMOZ","genericName":"ADALIMUMAB-ADAZ","slug":"adalimumab-adaz","indication":"Oncology","status":"marketed"},{"name":"LRG-002","genericName":"LRG-002","slug":"lrg-002","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"SOK583A1","genericName":"SOK583A1","slug":"sok583a1","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"GP2013 - A Proposed biosimilar rituximab","genericName":"GP2013 - A Proposed biosimilar rituximab","slug":"gp2013-a-proposed-biosimilar-rituximab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"HX575 epoetin alfa","genericName":"HX575 epoetin alfa","slug":"hx575-epoetin-alfa","indication":"Anemia of chronic kidney disease","status":"phase_3"},{"name":"HX575 epoetin alfa (Sandoz)","genericName":"HX575 epoetin alfa (Sandoz)","slug":"hx575-epoetin-alfa-sandoz","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Keytruda-EU","genericName":"Keytruda-EU","slug":"keytruda-eu","indication":"Metastatic melanoma","status":"phase_3"},{"name":"MabThera","genericName":"MabThera","slug":"mabthera","indication":"Relapsed or refractory B-cell non-Hodgkin's lymphoma","status":"marketed"},{"name":"Originator rituximab - Rituxan ® or MabThera ®","genericName":"Originator rituximab - Rituxan ® or MabThera ®","slug":"originator-rituximab-rituxan-or-mabthera","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"infectious","drugs":[{"name":"Adalimumab - US licensed Humira","genericName":"Adalimumab - US licensed Humira","slug":"adalimumab-us-licensed-humira","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Adalimumab - GP2017","genericName":"Adalimumab - GP2017","slug":"adalimumab-gp2017","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Angal S, topical spray [Menthol]","genericName":"Angal S, topical spray [Menthol]","slug":"angal-s-topical-spray-menthol","indication":"Topical relief of minor muscle and joint pain","status":"phase_3"},{"name":"GP2015 Etanercept","genericName":"GP2015 Etanercept","slug":"gp2015-etanercept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"GP2017 Adalimumab","genericName":"GP2017 Adalimumab","slug":"gp2017-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"TYRUKO","genericName":"NATALIZUMAB-SZTN","slug":"natalizumab-sztn","indication":"Multiple Sclerosis","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"rare","drugs":[{"name":"GP2411","genericName":"GP2411","slug":"gp2411","indication":"Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis)","status":"phase_3"},{"name":"Interleukin-3","genericName":"Interleukin-3","slug":"interleukin-3","indication":"Bone marrow failure and aplastic anemia","status":"marketed"},{"name":"LA-EP2006","genericName":"LA-EP2006","slug":"la-ep2006","indication":"Anemia of chronic kidney disease","status":"phase_3"},{"name":"US-licensed epoetin alfa","genericName":"US-licensed epoetin alfa","slug":"us-licensed-epoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Ocrevus-EU","genericName":"Ocrevus-EU","slug":"ocrevus-eu","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"},{"name":"Dopaminergic Agonists","genericName":"Dopaminergic Agonists","slug":"dopaminergic-agonists","indication":"Parkinson's disease","status":"marketed"},{"name":"Ocrevus-US","genericName":"Ocrevus-US","slug":"ocrevus-us","indication":"Relapsing multiple sclerosis","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"ANTI-ANGIN® FORMULA, topical metered spray","genericName":"ANTI-ANGIN® FORMULA, topical metered spray","slug":"anti-angin-formula-topical-metered-spray","indication":"Sore throat pain relief","status":"phase_3"},{"name":"Angal, lozenges [menthol],","genericName":"Angal, lozenges [menthol],","slug":"angal-lozenges-menthol","indication":"Sore throat pain and irritation","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CYB704","genericName":"CYB704","slug":"cyb704","indication":"Age-related macular degeneration (AMD)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"CIMERLI","genericName":"RANIBIZUMAB-EQRN","slug":"ranibizumab-eqrn","indication":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"HX575 epoetin alfa Hexal AG","genericName":"HX575 epoetin alfa Hexal AG","slug":"hx575-epoetin-alfa-hexal-ag","indication":"Anemia of chronic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"CYB704","genericName":"CYB704","slug":"cyb704","phase":"phase_3","mechanism":"CYB704 is a selective inhibitor of complement factor D that reduces complement cascade activation and downstream inflammatory responses.","indications":["Age-related macular degeneration (AMD)"],"catalyst":""},{"name":"EP2006","genericName":"EP2006","slug":"ep2006","phase":"phase_3","mechanism":"EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia in patients with chronic kidney disease","Chemotherapy-induced anemia in cancer patients"],"catalyst":""},{"name":"Ocrevus-EU","genericName":"Ocrevus-EU","slug":"ocrevus-eu","phase":"phase_3","mechanism":"Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Primary progressive multiple sclerosis (PPMS)"],"catalyst":""},{"name":"ANTI-ANGIN® FORMULA, topical metered spray","genericName":"ANTI-ANGIN® FORMULA, topical metered spray","slug":"anti-angin-formula-topical-metered-spray","phase":"phase_3","mechanism":"ANTI-ANGIN® FORMULA provides topical anesthetic and anti-inflammatory relief for sore throat and oral pain through local numbing and soothing agents.","indications":["Sore throat pain relief","Pharyngitis symptom management","Minor oral and throat irritation"],"catalyst":""},{"name":"Adalimumab - US licensed Humira","genericName":"Adalimumab - US licensed Humira","slug":"adalimumab-us-licensed-humira","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Depakote DR Tablets","genericName":"Depakote DR Tablets","slug":"depakote-dr-tablets","phase":"phase_1","mechanism":"Increases brain levels of gamma-aminobutyric acid (GABA) and modulates voltage-gated sodium channels to reduce neuronal excitability.","indications":[],"catalyst":""},{"name":"ERYPO®, Janssen-Cilag","genericName":"ERYPO®, Janssen-Cilag","slug":"erypo-janssen-cilag","phase":"phase_3","mechanism":"ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"GP2411","genericName":"GP2411","slug":"gp2411","phase":"phase_3","mechanism":"GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function.","indications":["Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis)","Mobilization of peripheral blood progenitor cells for autologous stem cell transplantation"],"catalyst":""},{"name":"HYRIMOZ","genericName":"ADALIMUMAB-ADAZ","slug":"adalimumab-adaz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"JUBBONTI","genericName":"DENOSUMAB-BBDZ","slug":"denosumab-bbdz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"LRG-002","genericName":"LRG-002","slug":"lrg-002","phase":"phase_3","mechanism":"LRG-002 is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Opana","genericName":"Opana","slug":"opana","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SOK583A1","genericName":"SOK583A1","slug":"sok583a1","phase":"phase_3","mechanism":"SOK583A1 is a small molecule drug that targets the molecular target.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"ANTI-ANGIN® FORMULA","genericName":"ANTI-ANGIN® FORMULA","slug":"anti-angin-formula","phase":"phase_3","mechanism":"Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload.","indications":["Angina pectoris (stable and unstable)","Prophylaxis of anginal attacks"],"catalyst":""},{"name":"Adalimumab - GP2017","genericName":"Adalimumab - GP2017","slug":"adalimumab-gp2017","phase":"phase_3","mechanism":"GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Angal S, topical spray [Menthol]","genericName":"Angal S, topical spray [Menthol]","slug":"angal-s-topical-spray-menthol","phase":"phase_3","mechanism":"Menthol produces a cooling sensation by activating TRPM8 cold-sensitive receptors on nerve endings, providing topical analgesic and anti-inflammatory relief.","indications":["Topical relief of minor muscle and joint pain","Symptomatic relief of minor aches and pains associated with arthritis, backache, and sprains"],"catalyst":""},{"name":"Angal, lozenges [menthol],","genericName":"Angal, lozenges [menthol],","slug":"angal-lozenges-menthol","phase":"phase_3","mechanism":"Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough.","indications":["Sore throat pain and irritation","Cough suppression"],"catalyst":""},{"name":"Broncho-munal®","genericName":"Broncho-munal®","slug":"broncho-munal","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CIMERLI","genericName":"RANIBIZUMAB-EQRN","slug":"ranibizumab-eqrn","phase":"marketed","mechanism":"","indications":["Neovascular (Wet) Age-Related Macular Degeneration (AMD)","Macular Edema Following Retinal Vein Occlusion (RVO)","Diabetic Macular Edema (DME)","Diabetic Retinopathy (DR)","Myopic Choroidal Neovascularization (mCNV)"],"catalyst":""},{"name":"Canasa","genericName":"Canasa","slug":"canasa","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dopaminergic Agonists","genericName":"Dopaminergic Agonists","slug":"dopaminergic-agonists","phase":"marketed","mechanism":"Dopaminergic agonists activate dopamine receptors in the brain to increase dopamine signaling.","indications":["Parkinson's disease","Restless leg syndrome","Hyperprolactinemia"],"catalyst":""},{"name":"Duragesic","genericName":"Duragesic","slug":"duragesic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ENZEEVU","genericName":"AFLIBERCEPT-ABZV","slug":"aflibercept-abzv","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"GME751","genericName":"GME751","slug":"gme751","phase":"phase_3","mechanism":"GME751 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"GP2013","genericName":"GP2013","slug":"gp2013","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GP2013 - A Proposed biosimilar rituximab","genericName":"GP2013 - A Proposed biosimilar rituximab","slug":"gp2013-a-proposed-biosimilar-rituximab","phase":"phase_3","mechanism":"GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","indications":["Rheumatoid arthritis","Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia","Granulomatosis with polyangiitis","Microscopic polyangiitis"],"catalyst":""},{"name":"GP2015","genericName":"GP2015","slug":"gp2015","phase":"phase_3","mechanism":"GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells.","indications":["Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy"],"catalyst":""},{"name":"GP2015 Etanercept","genericName":"GP2015 Etanercept","slug":"gp2015-etanercept","phase":"phase_3","mechanism":"GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Plaque psoriasis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"GP2017 Adalimumab","genericName":"GP2017 Adalimumab","slug":"gp2017-adalimumab","phase":"phase_3","mechanism":"GP2017 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated disease activity.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Psoriasis","Ankylosing spondylitis"],"catalyst":""},{"name":"Generic tacrolimus","genericName":"Generic tacrolimus","slug":"generic-tacrolimus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glimid","genericName":"GLUTETHIMIDE","slug":"glutethimide","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-3/gamma-2","indications":["Insomnia"],"catalyst":""},{"name":"Glucophage 1000 mg","genericName":"Glucophage 1000 mg","slug":"glucophage-1000-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HX575 epoetin alfa","genericName":"HX575 epoetin alfa","slug":"hx575-epoetin-alfa","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia","Anemia in patients with cancer"],"catalyst":""},{"name":"HX575 epoetin alfa (Sandoz)","genericName":"HX575 epoetin alfa (Sandoz)","slug":"hx575-epoetin-alfa-sandoz","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing major surgery"],"catalyst":""},{"name":"HX575 epoetin alfa Hexal AG","genericName":"HX575 epoetin alfa Hexal AG","slug":"hx575-epoetin-alfa-hexal-ag","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia","Anemia in patients with HIV infection"],"catalyst":""},{"name":"HX575 recombinant human erythropoietin alfa","genericName":"HX575 recombinant human erythropoietin alfa","slug":"hx575-recombinant-human-erythropoietin-alfa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Interleukin-3","genericName":"Interleukin-3","slug":"interleukin-3","phase":"marketed","mechanism":"Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages.","indications":["Bone marrow failure and aplastic anemia","Myelodysplastic syndromes","Chemotherapy-induced myelosuppression"],"catalyst":""},{"name":"Keytruda-EU","genericName":"Keytruda-EU","slug":"keytruda-eu","phase":"phase_3","mechanism":"Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"LA-EP2006","genericName":"LA-EP2006","slug":"la-ep2006","phase":"phase_3","mechanism":"LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia"],"catalyst":""},{"name":"MabThera","genericName":"MabThera","slug":"mabthera","phase":"marketed","mechanism":"MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","indications":["Relapsed or refractory B-cell non-Hodgkin's lymphoma","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"Ocrevus-US","genericName":"Ocrevus-US","slug":"ocrevus-us","phase":"phase_3","mechanism":"Ocrevus-US is a monoclonal antibody that targets CD20 on B cells.","indications":["Relapsing multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Omnitrope","genericName":"Omnitrope","slug":"omnitrope","phase":"marketed","mechanism":"Growth hormone receptor","indications":["Growth retardation","Pituitary dwarfism","Prader-Willi syndrome","Severe growth hormone deficiency in adulthood","Turner syndrome"],"catalyst":""},{"name":"Originator rituximab - Rituxan ® or MabThera ®","genericName":"Originator rituximab - Rituxan ® or MabThera ®","slug":"originator-rituximab-rituxan-or-mabthera","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"TYRUKO","genericName":"NATALIZUMAB-SZTN","slug":"natalizumab-sztn","phase":"marketed","mechanism":"","indications":["Multiple Sclerosis","Crohn's Disease"],"catalyst":""},{"name":"US-licensed epoetin alfa","genericName":"US-licensed epoetin alfa","slug":"us-licensed-epoetin-alfa","phase":"phase_3","mechanism":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor.","indications":["Anemia associated with chronic kidney disease","Anemia associated with chemotherapy"],"catalyst":""},{"name":"ZIEXTENZO","genericName":"PEGFILGRASTIM-BMEZ","slug":"pegfilgrastim-bmez","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":46,"phaseCounts":{"phase_3":28,"phase_1":2,"marketed":15,"discontinued":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}